The biotech company CureVac AG announced on August 10th, 2020, that it has applied to list its common shares on The Nasdaq Global Market under the ticker symbol “CVAC”. CureVac intends to offer and sell 13,333,333 common shares in an underwritten public offering. The initial public offering price is expected to be between $14.00 and $16.00 per common share.
Few weeks ago, CureVac had already announced the closing of a private financing round for a total sum of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and GlaxoSmithKline with USD 171 million. Equity investments have also been made by Qatar Investment Authority (QIA) and a group of existing and new investors with approximately USD 126 million.
CureVac is a leading biopharmaceutical company in the field of messenger RNA (mRNA) technology. With 20 years of expertise, CureVac is engaged in developing and optimizing this versatile molecule for medical purposes, including running clinical trials. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. In June, CureVac commenced clinical tests on a candidate for a Covid-19 vaccine.
Before the financing round just concluded, CureVac had already received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, GlaxoSmithKline, Genmab, CRISPR Therapeutics, CEPI, and the Bill & Melinda Gates Foundation. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
The following Gleiss Lutz team led by Dr. Christian Cascante (partner, M&A) is advising Dr. Ingmar Hoerr, founder and shareholder of CureVac: Dr. Stephan Aubel (partner, ECM, both Frankfurt), Dr. Christian Arnold (partner, Corporate Governance), Dr. Marco König (partner, Healthcare/Regulatory), Muriel Kaufmann (counsel, Corporate Governance) and Karen Gräfin vom Hagen (M&A/IP, all Stuttgart).